Business Context and Reporting Period
Company: American BriVision (Holding) Corporation (Note: Input metadata references "ABVC BIOPHARMA, INC.", but the filing text identifies the registrant as American BriVision (Holding) Corporation).
Filing Type: Form 8-K (Current Report)
Reporting Date: October 29, 2019
Event: Entry into a Material Definitive Agreement involving the sale of a convertible promissory note to an accredited investor.
Key Financial Metrics
Capital Raised: $250,000 (Principal Amount)
Instrument: Convertible Promissory Note
Interest Rate: 20% per annum
Conversion Price: Lower of (i) $0.50 per share or (ii) 70% of the per share offering price of a completed public equity offering exceeding $10,000,000.
Ownership Cap: Conversion is limited such that the holder and affiliates do not beneficially own more than 4.99% of outstanding common stock.
Debt and Liquidity: The filing does not provide clear values for total debt, cash flow, revenue, or overall liquidity positions beyond the specific $250,000 transaction.
Material Changes
- New Obligation: Creation of a direct financial obligation of $250,000 plus accrued interest.
- Equity Dilution Potential: Potential issuance of common stock upon conversion of the note, subject to the 4.99% beneficial ownership limitation.
- Cash Inflow: Immediate receipt of $250,000 from the investor on October 29, 2019.
Outlook, Risks, and Contingencies
Default Provisions: Upon an event of default, the entire unpaid principal and accrued interest become immediately due and payable.
Conversion Conditions: The conversion price is contingent on the company completing a public equity offering exceeding $10,000,000. If such an offering does not occur, the conversion price defaults to $0.50 per share (subject to adjustments).
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary beyond the terms of the agreement.
Investor Verification Checklist
- Verify the current cash position and whether the $250,000 infusion addresses immediate liquidity needs.
- Confirm the total number of outstanding shares to calculate the potential dilution impact of the 4.99% ownership cap.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 10.2) for specific default triggers and adjustment mechanisms.
- Assess the company's progress toward a public equity offering exceeding $10,000,000, which influences the conversion price.
- Check for any subsequent filings regarding the status of this note or additional financing activities.